Stock ALTME TME PHARMA N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases TME Pharma N.V.

Equities

ALTME

NL0015000YE1

Market Closed - Euronext Paris
Other stock markets
 11:21:58 2024-05-02 EDT 		5-day change 1st Jan Change
0.2435 EUR -4.51% Intraday chart for TME Pharma N.V. -5.07% +5.87%
04-25 TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
04-23 TME Pharma N.V. Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two-Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer CI

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
TME Pharma Publishes 2023 Financial Results and Provides Operating Update
BU
TME PHARMA ANNOUNCES 33% OF PATIENTS RECEIVING NOX-A12 IN COMBINATION WITH BEVACIZUMAB AND RADIOTHERAPY ACHIEVE TWO-YEAR SURVIVAL IN GLORIA PHASE 1/2 TRIAL IN BRAIN CANCER
AQ
TME Pharma Announces 33% of Patients Receiving NOX-A12 in Combination With Bevacizumab and Radiotherapy Achieve Two‑Year Survival in GLORIA Phase 1/2 Trial in Brain Cancer
BU
TME Pharma N : Inside Information / Other news releases
PU
TME Pharma Receives US FDA Fast Track Designation for Lead Asset NOX-A12 in Brain Cancer
BU
TME Pharma N : receives US FDA Fast Track designation for lead asset NOX-A12 in brain cancer
PU
TME Pharma Provides Results of First Exercise of Warrants Z
BU
TME PHARMA PROVIDES RESULTS OF FINAL EXERCISE OF WARRANTS Y: ADDITIONAL EUR854K RAISED AND EXTENSION OF CASH RUNWAY FROM MAY INTO JULY 2024
AQ
TME PHARMA PROVIDES UPDATE ON NUMBER OF OUTSTANDING SHARES AND WARRANTS FOLLOWING FIRST WARRANT Y EXERCISE PERIOD
AQ
TME Pharma N : Inside Information / Other news releases
PU
TME PHARMA ANNOUNCES RESULTS OF SUCCESSFUL CAPITAL INCREASE WITH PREFERENTIAL SUBSCRIPTION RIGHTS FOR EUR2.7 MILLION
AQ
TME PHARMA ANNOUNCES THE INITIATION OF THE LISTING OF PREFERENTIAL SUBSCRIPTION RIGHTS FOR FULLY GUARANTEED EUR2.7 MILLION CAPITAL INCREASE
AQ
TME PHARMA LAUNCHES FULLY GUARANTEED EUR2.7 MILLION PREFERENTIAL RIGHTS ISSUE WITH WARRANTS ATTACHED COMBINED WITH BUYBACK OF CONVERTIBLE DEBT
AQ
TME Pharma N : Inside Information / Operations of the issuer (acquisitions, sales...)
PU
TME PHARMA ANNOUNCES ADDITIONAL DATA FROM NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER PRESENTED AT SNO 2023 ANNUAL MEETING
AQ
TME PHARMA REPORTS H1 2023 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE
AQ
TME PHARMA ANNOUNCES FURTHER IMPROVEMENT IN OVERALL SURVIVAL AT 18 MONTHS TO 67% FOR NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER
AQ
TME PHARMA REPORTS ON END OF SIX-MONTH LOCK-UP PERIOD OF SHARES AND CONVERTIBLE BONDS FOLLOWING THE APRIL 2023 TRANSACTION
AQ
TME Pharma N : Inside Information / Other news releases
PU
TME PHARMA PROVIDES POSITIVE UPDATE ON 18-MONTH SURVIVAL FOR NOX-A12 COMBINATION REGIMEN IN BRAIN CANCER AND PROVIDES STRATEGIC UPDATE INCLUDING DECISION TO ENGAGE WITH US FDA
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ALTME Stock
  4. News TME Pharma N.V.
  5. Press Releases